Carvedilol is a non-selective beta blocker with antioxidant properties approved for use in congestive heart failure. Carvedilol also possesses potent antioxidant and antiproliferative actions.

However, despite improvements in ejection fraction with both carvedilol and metoprolol, an increase in beta receptor density is seen only with metoprolol. [11] Beta blockers, including carvedilol ...

In the year 2007, the company launched Carzec (carvedilol) and Zemetril (cefprozil). In March 2007, the company opened new Medicinal Chemistry Laboratory at their R&D facility in Singapore.